Physicians' Academy for Cardiovascular Education

CV Inflammation

Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.

Detecting residual cardiovascular risk using coronary CT angiography

10' education - Oct. 18, 2021 - Prof. Charalambos Antoniades, MD, PhD

Novel modulators of inflammation in atherosclerosis

10' education - Oct. 6, 2021 - Prof. Peter Libby, MD

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD

Anti-inflammation heralds the future of CV medicine

10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD

Strong evidence for colchicine in patients with chronic coronary disease

5' education - Oct. 7, 2020 - Aernoud Fiolet, MD and prof. Jan Hein Cornel, MD, PhD

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia

Succesful repurposing of an old anti-inflammatory drug for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia

Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia

CRP levels associated with risk of cancer in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

Challenges in targeting residual risk in diabetic patients, post ACS

10' education - Sep. 25, 2019 - Prof. Peter Libby, MD

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation

3' education - May 28, 2019 - EAS 2019, Maastricht - Paul Ridker, MD

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Neutral study with methotrexate offers interesting insights on CV-relevant inflammatory pathway

3' education - Nov. 11, 2018

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA

What is the situation one year after the presentation about the CANTOS trial?

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA
Also as CME e-learning

Inflammation & CVD: Translating insights from vascular biology to the clinic

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME
Also as CME accredited e-learning

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME

The patient with inflammatory residual risk: Who is it?

10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Analogous to LDL-c, the lower the better also seems true for inflammation

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

Detecting residual cardiovascular risk using coronary CT angiography

10' education - Oct. 18, 2021 - Prof. Charalambos Antoniades, MD, PhD
Charalambos Antoniades explains why coronary inflammation needs to be diagnosed and treated and shows how perivascular fat analysis from routine CTCA can provide a quantitative assessment of coronary inflammation.

Charalambos Antoniades explains why coronary inflammation needs to be diagnosed and treated and shows how perivascular fat analysis from routine CTCA can provide a quantitative assessment of coronary inflammation.

Novel modulators of inflammation in atherosclerosis

10' education - Oct. 6, 2021 - Prof. Peter Libby, MD
Prof. Peter Libby brings us up to date on some novel aspects of inflammation in atherosclerosis.

Prof. Peter Libby brings us up to date on some novel aspects of inflammation in atherosclerosis.

Reduced cardiac adipose tissue by GLP-1RA in T2DM

News - Oct. 4, 2021

EASD 2021 Cardiac adipose tissue measured by CT was reduced by treatment with liraglutide compared to placebo in patients with T2DM, but this reduction was dependent on changes in weight loss.

hsCRP reduced by GLP-1RA in patients with T2DM

News - Oct. 1, 2021

EASD 2021 Using data of four semaglutide trials, this exploratory analysis showed that both subcutaneous and oral semaglutide reduced high-sensitivity CRP in patients with T2DM.

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD
What is the relationship between triglyceride-rich lipoproteins and CV risk? And what is the role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins? Peter Libby answers these and other questions in this video.

What is the relationship between triglyceride-rich lipoproteins and CV risk? And what is the role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins? Peter Libby answers these and other questions in this video.

IL-6 levels in the general population associated with new-onset HFpEF

Literature - June 28, 2021 - Chia YC et al. - J Am Heart Assoc. 2021

Levels of IL-6 in community-dwelling participants were associated with the development of HFpEF, independent of iron deficiency, anemia, and FGF23 upregulation.

Biomarkers of inflammation predict HF hospitalization and adverse outcomes in AF

Literature - June 14, 2021 - Benz AP, et al. - J Am Heart Assoc. 2021

This combined cohort study suggested that IL-6 and hs-CRP levels were associated with HF hospitalization and adverse outcomes in patients with AF. The risk for HF hospitalization increased with increasing inflammation scores of both inflammation markers.

Novel IL-6 inhibitor largely reduces hsCRP in CKD with elevated hsCRP

News - May 19, 2021

ACC 2021 The phase 2 RESCUE trial showed that the IL-6 inhibitor ziltivekimab largely reduced hsCRP and other biomarkers of inflammation and thrombosis in patients with CKD and ≥2 mg/L hsCRP.

Consistent CV benefit of colchicine in patients with coronary disease

Literature - Apr. 19, 2021 - Fiolet ATL et al. - Eur Heart J 2021

A meta-analysis of 5 trials showed that colchicine reduced MACE by 25% compared to placebo or no colchicine with a low between-trial heterogeneity in a wide range of patients with coronary disease.

Anti-inflammation heralds the future of CV medicine

10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD
From CANTOS to COLCOT to COPS to LoDoCo2: What are the lessons from these trials with anti-inflammatory treatment, in particular those with colchicine, in patients with residual inflammatory risk?

From CANTOS to COLCOT to COPS to LoDoCo2: What are the lessons from these trials with anti-inflammatory treatment, in particular those with colchicine, in patients with residual inflammatory risk?

Anti-inflammatory treatment within 3 days after MI improves CV outcomes

Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

Literature - Jan. 25, 2021 - Bouabdallaoui N, et al. - Eur Heart J. 2020

A subanalysis of COLCOT showed that initiation of colchicine within the first 3 days after MI significantly reduced the risk of an ischemic CV event compared to patients on placebo.

Endothelial injury and dysfunction in COVID-19

Literature - Jan. 19, 2021 - Evans PC et al., - Cardiovasc Res. 2020

This position paper discusses the cause and consequences of endothelial injury and dysfunction in COVID-19.